ArticleBJU international2022
Large variation in conservative management of low-risk prostate cancer in Australia and New Zealand.
Article in BJU international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Current application of blockchain technology in healthcare and its potential roles in Urology.BJU international · 2025Pooled it
- Impact of the diagnostic label for a low-risk prostate lesion: protocol for two online factorial randomised experiments.BMJ open · 2024Article
- Co-designing an online treatment decision aid for men with low-risk prostate cancer: Navigate.BJUI compass · 2024Article
- Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer.JAMA network open · 2023Article
- Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.The Prostate · 2023Review
- Women's views about current and future management of Ductal Carcinoma in Situ (DCIS): A mixed-methods study.PloS one · 2023Article
- Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review.Prostate international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.